Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma
Open Access
- 1 March 2017
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 484 (2) , 269-277
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea (2015R1A1A3A04001051)
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Education (15K15100, 2014R1A1A2057903, 2016R1D1A1B03931785, 26293088)
- Ministry of Science, ICT and Future Planning (2015-001923, 2015-001937)
This publication has 38 references indexed in Scilit:
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerProceedings of the National Academy of Sciences, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell LinesPLOS ONE, 2009
- Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasJournal of Clinical Investigation, 2007
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2Cancer Cell, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6Science, 1994